Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: August 14, 2022

Claims for Patent: 7,544,373

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,544,373
Title:Minocycline oral dosage forms for the treatment of acne
Abstract:Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:11/695,539
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,544,373
Patent Claims: 1. A minocycline oral dosage form for the treatment of acne, comprising: (i) an intragranular blend of: 90 mg of minocycline hydrochloride; 108 mg of the matrix-forming polymer hydroxypropyl methylcellulose; and 152 mg of an intragranular lactose, wherein the matrix-forming polymer hydroxypropyl methylcellulose is a slow dissolving carrier; and (ii) 41 mg of extragranular lactose monohydrate, wherein the extragranular lactose is a fast dissolving carrier, a portion of which completely or partially encapsulates or coats the intragranular blend; (iii) 3.0 mg of silicon oxide; and (iv) 6.0 mg of magnesium stearate, wherein the dosage form has a total weight of 400 mg and provides a patient with about 1 mg/kg of the minocycline in a slow, continuous fashion, without an initial load dose, that effectively treats acne of the patient by the once daily administration of the dosage form.

2. A kit comprising: the minocycline oral dosage form of claim 1; and information that the oral dosage form may cause one or more adverse effects.

3. The kit of claim 2, wherein the one or more adverse effects is selected from group consisting of one or more of: headache, fatigue, dizziness, pruritus, malaise, mood alteration, somnolence, urticaria, tinnitus, vertigo, dry mouth, and myalgia.

4. The kit of claim 3, further comprising additional information about one or more deleterious effects selected from the group consisting of: gastrointestinal disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

5. The kit of claim 2, further comprising instructions for administering the oral dosage form.

6. The minocycline oral dosage form of claim 1, further comprising a film coat.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.